FLT3 and acute myeloid leukemia: Thus, sustained inhibition of the FLT3 receptor using a highly selective second-generation inhibitor [12] like gilteritinib can help restore normal hematopoiesis in patients with FLT3mut+ R/R AML by targeting residual FLT3-driven AML clones, which ultimately lowers relapse risk and improves outcomes in this high-risk population [9, 10].